Monday 05.13.2024 7:10 AM |
Welcome Guest Main | Registration | Login | RSS |
Calendar |
---|
« December 2022 » | Su | Mo | Tu | We | Th | Fr | Sa | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 |
|
|
My site
BlogMain » 2022 » December » 08
INGELHEIM, Germany & INDIANAPOLIS - Wednesday, 07. December 2022
Jardiance® (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged 10-17 living with type 2 diabetes compared to placebo
Safety data in this vulnerable population was similar to that in adults with type 2 diabetes, confirming the well-established safety profile of empagliflozin
(BUSINESS WIRE)--The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012)
...
Read more »
|
|
|